Concelizumab price information and purchasing guide

Concizumab (Concizumab), as an innovative biological agent for hemophilia A and B, has been launched since 2024FDA) on December 20, 2019, it has attracted the attention of hemophilia patients around the world.

Cancelizumab is particularly indicated for those with hemophiliaA (congenital factorVIII deficiency) with aFVIII inhibitor or with FIX Inhibitors for the treatment of hemophiliaB (congenital factor IX deficiency) in adults and children aged 12 years and older, for routine prophylaxis to prevent or reduce the frequency of bleeding events.

However, for domestic patients, purchasing cancelizumab is not easy. Since the drug is not currently on the market in China, patients cannot purchase it directly from domestic pharmacies or hospitals. This situation makes many patients confused about the price information and purchasing methods of cancelizumab.

Regarding the price of cancelizumab, due to its short time on the market and the pricing strategies of various countries and regions may be different, the current price information is not clear yet. Patients can consult local hospitals and pharmacies to learn about relevant drug information or alternative treatment options.

As for the purchasing channel, it is indeed difficult for domestic patients to directly purchase cancelizumab. Urgently needed patients can obtain it through overseas channels or cross-border medical services. However, there are certain risks and uncertainties in this method, and patients need to choose formal institutions carefully. At the same time, patients can pay attention to the dynamics of domestic pharmaceutical policies in a timely manner to learn whether it is possible to introduce the drug through special channels.

Cancelizumab, as a new biological agent for hemophilia, provides patients with a new treatment option. Although it is currently difficult to purchase domestically, with the continuous advancement of medical technology and the increasing convenience of international trade, it is believed that more patients will be able to benefit from the treatment of this drug in the future. At the same time, patients should also maintain a positive attitude, actively consult professionals, and explore treatment options that suit them.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761315s000lbl.pdf